Xilio Therapeutics appoints new President, CMO, CDO; Huber resigns to pursue CEO role

Xilio Therapeutics, Inc.

Martin Huber, M.D., resigns as President and Head of R&D effective Sept 8; remains advisor.
CEO René Russo adds President title; previously served as President in 2021-2022.
Katarina Luptakova promoted to CMO; succeeds Huber with 20 years of oncology drug development experience.
Scott Coleman promoted to CDO; over 25 years in biotech, including at Acceleron and Merck.
Kevin Brennan enters employment agreement (base $370K, 35% bonus target) as SVP Finance.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

René Russo

President

XLO · Xilio Therapeutics, Inc.

Effective: 2023-09-08
Filed: September 5, 2023, 7:59 PM ET

Effective September 8, 2023, the board of directors (the “Board”) of the Company appointed René Russo, Pharm.D., 48, to President of the Company.

Departed

Martin Huber

President and Head of Research and Development

XLO · Xilio Therapeutics, Inc.

Effective: 2023-09-08
Successor: René Russo
Filed: September 5, 2023, 7:59 PM ET

Martin Huber, M.D., notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as President and Head of Research and Development of the Company, effective September 8, 2023, to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

René Russo was appointed as President at Xilio Therapeutics, Inc..

Action: appointed
Role: President

Exact text from the filing

Effective September 8, 2023, the board of directors (the “Board”) of the Company appointed René Russo, Pharm.D., 48, to President of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin Huber resigned as President and Head of Research and Development at Xilio Therapeutics, Inc..

Action: resigned
Role: President and Head of Research and Development

Exact text from the filing

Martin Huber, M.D., notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as President and Head of Research and Development of the Company, effective September 8, 2023, to pursue other opportunities.

View on SEC.gov

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-015426

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.